KTRA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KTRA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Kintara Therapeutics's Cash per Share for the quarter that ended in Dec. 2023 was $0.07.
The historical data trend for Kintara Therapeutics's Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintara Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | |||||||||||
Cash per Share | Get a 7-Day Free Trial | 48.43 | 10.44 | 16.09 | 8.99 | 0.91 |
Kintara Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cash per Share | Get a 7-Day Free Trial | 2.91 | 1.80 | 0.91 | 0.12 | 0.07 |
This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.
Kintara Therapeutics's Cash per Share for the fiscal year that ended in Jun. 2023 is calculated as:
Cash per Share | = | Cash, Cash Equivalents, Marketable Securities | / | Shares Outstanding (EOP) |
= | 1.535 | / | 1.69 | |
= | 0.91 |
Kintara Therapeutics's Cash per Share for the quarter that ended in Dec. 2023 is calculated as:
Cash per Share | = | Cash, Cash Equivalents, Marketable Securities | / | Shares Outstanding (EOP) |
= | 0.658 | / | 10.17 | |
= | 0.06 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintara Therapeutics (NAS:KTRA) Cash per Share Explanation
Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.
Thank you for viewing the detailed overview of Kintara Therapeutics's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert Hoffman | director, officer: President and CEO | ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121 |
Anthony Scott Praill | officer: Chief Financial Officer | 2001-889 HOMER STREET, VANCOUVER A1 V6B 5S3 |
Saiid Zarrabian | director, officer: Head of Strategic Partnerships | P.O. BOX 675765, RANCHO SANTA FE CA 92067 |
Laura L. Johnson | director | C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122 |
Tamara A Seymour | director | C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008 |
Toth Robert Joseph Jr | director | 543 LOMBARD ST, SAN FRANCISCO CA 94133 |
Dennis M Brown | officer: Chief Scientific Officer | 100 SAN MATEO DR, MENLO PARK CA 94025 |
Keith Murphy | director | 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121 |
John Liatos | director, officer: SVP, Business Development | 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
John K Bell | director | 38 FALLBROOK LANE RR 33, CAMBRIDGE A6 N3H 4R8 |
Napoleone Ferrara | director | 550 FRONT STREET, UNIT 1103, SAN DIEGO CA 92101 |
Lynda Sarah Cranston | director | 4316 LOCARNO CRESCENT, VANCOUVER A1 V6R 1G3 |
Erich Mohr | director | 8300 GREENSBORO DRIVE, MCLEAN VA 22102 |
Jeffrey Bacha | director | SUITE 3 1545 WEST 14TH AVENUE, VANCOUVER A1 V6J 2J1 |
William J Garner | director | 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010 |
From GuruFocus
By PRNewswire PRNewswire • 01-09-2023
By PRNewswire PRNewswire • 08-09-2022
By PRNewswire PRNewswire • 05-08-2023
By PRNewswire • 12-07-2023
By PRNewswire • 10-31-2023
By PRNewswire PRNewswire • 05-11-2023
By PRNewswire • 07-19-2023
By PRNewswire • 11-14-2023
By PRNewswire • 12-05-2023
By PRNewswire PRNewswire • 06-16-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.